116 related articles for article (PubMed ID: 35103198)
1. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis.
Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A
Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
Pathan S
Hosp Pharm; 2024 Aug; 59(4):394-406. PubMed ID: 38919755
[No Abstract] [Full Text] [Related]
4. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa versus Four-Factor Prothrombin Complex Concentrate for the Reversal of Factor Xa (FXa) Inhibitor-Associated Intracranial Hemorrhage: A Systematic Review of Retrospective Studies.
Ferreira LO; Oldemburg RAL; Leitão Filho JM; Cerveira RA; Vasconcelos VW; da Costa GE; Rodrigues RDR; Lopes DCF
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892788
[No Abstract] [Full Text] [Related]
7. 4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
Estroff JM; Devlin J; Hoteit L; Hassoune A; Neal MD; Brown JB; Lu L; Kotch S; Hazelton JP; Christian AB; Yeates EO; Nahmias J; Jacobson LE; Williams J; Schuster KM; O'Connor R; Semon GR; Straughn AD; Cullinane D; Egodage T; Kincaid M; Rollins A; Amdur R; Sarani B
J Trauma Acute Care Surg; 2024 Apr; ():. PubMed ID: 38685190
[TBL] [Abstract][Full Text] [Related]
8. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis.
Orso D; Fonda F; Brussa A; Comisso I; Auci E; Sartori M; Bove T
Crit Care; 2024 Jul; 28(1):221. PubMed ID: 38970010
[TBL] [Abstract][Full Text] [Related]
9. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
Phillips A; Bradley C; Cash J; Sangiovanni R; Wingerson C
Am J Health Syst Pharm; 2024 May; 81(11):e274-e282. PubMed ID: 38430127
[TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
[TBL] [Abstract][Full Text] [Related]
11. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
Connolly SJ; Sharma M; Cohen AT; Demchuk AM; Członkowska A; Lindgren AG; Molina CA; Bereczki D; Toni D; Seiffge DJ; Tanne D; Sandset EC; Tsivgoulis G; Christensen H; Beyer-Westendorf J; Coutinho JM; Crowther M; Verhamme P; Amarenco P; Roine RO; Mikulik R; Lemmens R; Veltkamp R; Middeldorp S; Robinson TG; Milling TJ; Tedim-Cruz V; Lang W; Himmelmann A; Ladenvall P; Knutsson M; Ekholm E; Law A; Taylor A; Karyakina T; Xu L; Tsiplova K; Poli S; Kallmünzer B; Gumbinger C; Shoamanesh A;
N Engl J Med; 2024 May; 390(19):1745-1755. PubMed ID: 38749032
[TBL] [Abstract][Full Text] [Related]
12. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
Lu G; Lin J; Bui K; Curnutte JT; Conley PB
Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
[TBL] [Abstract][Full Text] [Related]
13. Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT).
Deng H; Nutescu EA; DiDomenico RJ
Clin Appl Thromb Hemost; 2023; 29():10760296231176808. PubMed ID: 37272034
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors.
Goldin M; Smith K; Koulas I; Leung T; Ravi M; Parhar S; Shah S; Floyd K; Ohanesian L; Bain R; Defonte D; Ochani K; Lin A; Patel B; Tsaftaridis N; Jnani J; Spyropoulos AC
TH Open; 2024 Apr; 8(2):e209-e215. PubMed ID: 38741610
[No Abstract] [Full Text] [Related]
15. Hemostatic Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Doac-Associated Intracranial Hemorrhage.
Whaley PM; Franco-Martinez C; Lock AE; Ramaswamy D; Young EH; Allen SM; Barthol CA
J Pharm Pract; 2024 Jun; 37(3):557-562. PubMed ID: 36564900
[No Abstract] [Full Text] [Related]
16. Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.
Frol S; Oblak JP; Šabovič M; Kermer P
CNS Drugs; 2023 Jun; 37(6):477-487. PubMed ID: 37133623
[TBL] [Abstract][Full Text] [Related]
17. Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring.
Yagi T; Kawano R; Tomokage T; Ayata R; Koga Y; Kaneda K; Fujita M; Yamanaka N; Mori N; Tsuruta R
Acute Med Surg; 2024; 11(1):e954. PubMed ID: 38655507
[TBL] [Abstract][Full Text] [Related]
18. Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with Meta-Analysis.
Li JP; Li Y; Li B; Bian CH; Zhao F
Braz J Cardiovasc Surg; 2024 Apr; 39(2):e20230076. PubMed ID: 38568885
[TBL] [Abstract][Full Text] [Related]
19. Four-factor Prothrombin Complex Concentrate During Liver Transplantation: A Retrospective Cohort Study.
Lee J; Rivero A; Renew JR; Spaulding A; Borkar S; Mckenzie I; Davey K; Ladlie B
Transplant Direct; 2024 Jun; 10(6):e1637. PubMed ID: 38769975
[TBL] [Abstract][Full Text] [Related]
20. Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study.
Vellek J; Tarawneh OH; Kazim SF; Owodunni OP; Arbuiso S; Shah S; Dicpinigaitis AJ; Schmidt MH; McKee RG; Miskimins R; Al-Mufti F; Bowers CA
World Neurosurg X; 2024 Jul; 23():100367. PubMed ID: 38590738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
